CN103610645B - A kind of pharmaceutical composition of fexofenadine hydrochloride and preparation method - Google Patents
A kind of pharmaceutical composition of fexofenadine hydrochloride and preparation method Download PDFInfo
- Publication number
- CN103610645B CN103610645B CN201310606048.2A CN201310606048A CN103610645B CN 103610645 B CN103610645 B CN 103610645B CN 201310606048 A CN201310606048 A CN 201310606048A CN 103610645 B CN103610645 B CN 103610645B
- Authority
- CN
- China
- Prior art keywords
- composition
- mass percentage
- percentage content
- fexofenadine hydrochloride
- content
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- RRJFVPUCXDGFJB-UHFFFAOYSA-N Fexofenadine hydrochloride Chemical group Cl.C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RRJFVPUCXDGFJB-UHFFFAOYSA-N 0.000 title claims abstract description 29
- 229960000354 fexofenadine hydrochloride Drugs 0.000 title claims abstract description 29
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 9
- 238000002360 preparation method Methods 0.000 title description 9
- 239000000203 mixture Substances 0.000 claims abstract description 30
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 11
- 235000009508 confectionery Nutrition 0.000 claims description 15
- 235000014121 butter Nutrition 0.000 claims description 13
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 12
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 12
- 229930006000 Sucrose Natural products 0.000 claims description 12
- 239000005720 sucrose Substances 0.000 claims description 12
- 108010011485 Aspartame Proteins 0.000 claims description 11
- 239000000605 aspartame Substances 0.000 claims description 11
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 11
- 235000010357 aspartame Nutrition 0.000 claims description 11
- 229960003438 aspartame Drugs 0.000 claims description 11
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 claims description 11
- 239000007968 orange flavor Substances 0.000 claims description 11
- 235000014101 wine Nutrition 0.000 claims description 11
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 8
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 8
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 8
- 229920001285 xanthan gum Polymers 0.000 claims description 7
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims description 6
- 239000012467 final product Substances 0.000 claims description 6
- 238000012856 packing Methods 0.000 claims description 6
- 239000000377 silicon dioxide Substances 0.000 claims description 6
- 229960003592 fexofenadine Drugs 0.000 claims description 5
- 238000007873 sieving Methods 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 3
- 229910003978 SiClx Inorganic materials 0.000 claims 1
- 239000000375 suspending agent Substances 0.000 abstract description 12
- 239000000945 filler Substances 0.000 abstract description 11
- 235000003599 food sweetener Nutrition 0.000 abstract description 10
- 239000003765 sweetening agent Substances 0.000 abstract description 10
- 239000003814 drug Substances 0.000 description 6
- 239000002775 capsule Substances 0.000 description 4
- 238000005286 illumination Methods 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 3
- 241000206575 Chondrus crispus Species 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- XINCECQTMHSORG-UHFFFAOYSA-N Isoamyl isovalerate Chemical compound CC(C)CCOC(=O)CC(C)C XINCECQTMHSORG-UHFFFAOYSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 3
- 239000004376 Sucralose Substances 0.000 description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 3
- 239000000440 bentonite Substances 0.000 description 3
- 229910000278 bentonite Inorganic materials 0.000 description 3
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 3
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 235000019700 dicalcium phosphate Nutrition 0.000 description 3
- 235000012907 honey Nutrition 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229920001206 natural gum Polymers 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 229940085605 saccharin sodium Drugs 0.000 description 3
- 239000000661 sodium alginate Substances 0.000 description 3
- 235000010413 sodium alginate Nutrition 0.000 description 3
- 229940005550 sodium alginate Drugs 0.000 description 3
- 229940013618 stevioside Drugs 0.000 description 3
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 3
- 235000019202 steviosides Nutrition 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 235000019408 sucralose Nutrition 0.000 description 3
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 3
- 239000000811 xylitol Substances 0.000 description 3
- 235000010447 xylitol Nutrition 0.000 description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 3
- 229960002675 xylitol Drugs 0.000 description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 235000005976 Citrus sinensis Nutrition 0.000 description 1
- 240000002319 Citrus sinensis Species 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical class C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000009285 allergic inflammation Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000030949 chronic idiopathic urticaria Diseases 0.000 description 1
- 206010072757 chronic spontaneous urticaria Diseases 0.000 description 1
- 208000024376 chronic urticaria Diseases 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000000938 histamine H1 antagonist Substances 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
The pharmaceutical composition that the present invention relates to a kind of fexofenadine hydrochloride, said composition consists of the following composition: active component fexofenadine hydrochloride, content 1%-12%; Suspending agent content is 1%-10%; Filler content is 5%-85%; Levels of sweetener is 1%-10%; Essence content is 0.01%-10%; The glidant of convention amount, wherein said composition exists with the form of dry suspensoid agent. Fexofenadine hydrochloride dry suspensoid agent of the present invention have decentralization high, be evenly distributed, absorb fast, the advantage such as bioavilability is high, and mouthfeel is good and stablize.
Description
Technical field
The present invention relates to pharmaceutical, particularly a kind of novel form of fexofenadine hydrochloride and preparation method thereof.
Background technology
CAS registration number: 138452-21-8
Fexofenadine is the active metabolite of RMI 9918, is a kind of potent H1 receptor antagonist, do not have its predecessor thatThe cardiac toxic of sample. Decapacitation blocking-up H1 is subject to external, and in vivo and in vitro also shows, Fexofenadine is surely by mast cell, basophillaThe allergic inflammation reaction of granulocyte, epithelial cell, eosinophil and cell mediated. Confirm fexofenadine toolThere is anti-inflammatory activity, and can suppress in vitro the expression of ICAM-1 in nasal epithelial cells. Be used for the treatment of seasonal mistakeQuick property rhinitis and chronic idiopathic urticaria.
Fexofenadine has capsule, tablet, oral disnitegration tablet, oral administration mixed suspension for the conventional dosage forms of selection of clinical. Capsule, sheetAgent is a kind of general formulation, absorbs in vivo and must could pass through intestines and stomach arrival blood circulation through processes such as disintegration, strippings,And capsule, tablet are in process of production, are often difficult to disintegration because the reason such as auxiliary material, technique causes tablet, medicine is difficult to stripping, fromAnd make medicine not reach due therapeutic action. In addition, for the disease of children and dysphagia, capsule, tablet are difficult to accept.Disintegration fast in oral cavity that oral disnitegration tablet can be under anhydrous condition (or only having a small amount of water to exist), enters and disappears with swallowing actChange road, in oral cavity, without mucosa absorption, absorption in body, metabolic process are consistent with conventional tablet. Oral disnitegration tablet medicine requiresEfficiently, the medicine of low dosage, be not suitable for bitterness sense or the heavier medicine of excitant taste, preparation process complexity, disintegration time limited andDissolution rate is difficult to control, Chen Bengao. Although oral administration mixed suspension has overcome above shortcoming, must add anticorrosion at oral administration mixed suspensionAgent, to prevent the growth of bacterium, and be inconvenient to produce, storage and transport.
Summary of the invention
The present invention, in order to overcome the deficiencies in the prior art, provides a kind of dry suspensoid agent, has taking convenience, and decentralization is high, distributionEvenly, absorb soon, the advantage such as bioavilability is high, and mouthfeel is good and stablize, can overcome the shortcoming of conventional medicament composition,Layoutprocedure is simple simultaneously, but does not affect drug effect and other performances.
On the one hand, the invention provides a kind of pharmaceutical composition of fexofenadine hydrochloride, it is characterized in that, said composition by withLower one-tenth is grouped into: active component fexofenadine hydrochloride, mass percentage content 1%-12%; Suspending agent mass percentage contentFor 1%-10%; Filler mass percentage content is 5%-85%; Sweetener mass percentage content is 1%-10%; Essence qualityDegree is 0.01%-10%; The glidant of convention amount, wherein, said composition exists with the form of dry suspensoid agent.
Preferably, suspending agent is selected from PVP, xanthans, and bentonite, natural gum, polyethylene glycol, sodium carboxymethylcellulose,Methylcellulose, Hydroxypropyl methylcellulose, one or more in Tween-80, carragheen, carbopol and sodium alginate make simultaneouslyWith.
Preferably, filler is selected from lactose, sucrose, microcrystalline cellulose, sweet mellow wine, dextrin, calcium monohydrogen phosphate and pregelatinized starchIn one or more.
Preferably, sweetener be selected from a kind of of saccharin sodium, xylitol, Aspartame, stevioside, Sucralose, honey element orMultiple use simultaneously, content is 1%-10%; Essence is selected from the one of flavoring orange essence, flavoring apple essence, orange flavor, butter essenceOr multiple.
A pharmaceutical composition for fexofenadine hydrochloride, is characterized in that, said composition consists of the following composition: active one-tenthPoint fexofenadine hydrochloride, sodium carboxymethylcellulose, sweet mellow wine, sucrose, Aspartame, orange flavor, butter essence andSilica, wherein the mass percentage content of fexofenadine hydrochloride is 6%; The degree of sodium carboxymethylcellulose is5%; The mass percentage content of sweet mellow wine is 42%; The mass percentage content of sucrose is 40%; The mass percent of AspartameContent is 5%; Orange flavor mass percentage content is 0.5%; Butter essence mass percentage content is 0.5%; SilicaMass percentage content be 1.0%, wherein, said composition exists with the form of dry suspensoid agent.
A pharmaceutical composition for fexofenadine hydrochloride, is characterized in that, said composition consists of the following composition: active one-tenthDivide fexofenadine hydrochloride, xanthans, sweet mellow wine, sucrose, Aspartame, orange flavor, butter essence and silica,Wherein the mass percentage content of fexofenadine hydrochloride is 6%; The mass percentage content of xanthans is 5%; The matter of sweet mellow wineAmount degree is 42%; The mass percentage content of sucrose is 40%; The mass percentage content of Aspartame is 5%; SweetOrange essence mass percentage content is 0.5%; Butter essence mass percentage content is 0.5%; The mass percent of silica containsAmount is 1.%, and wherein, said composition exists with the form of dry suspensoid agent.
On the other hand, the invention provides a kind of preparation method of fexofenadine hydrochloride pharmaceutical composition, comprise the following steps:(1) fexofenadine hydrochloride and suspending agent are crossed to 80 mesh sieves; (2) by filler, sweetener, essence respectively becomes with glidantDivided 100 mesh sieves; (3) the each composition after sieving mixes, packing and get final product.
Preferably, the content 1%-12% of active component fexofenadine hydrochloride; Suspending agent content is 1%-10%; Filler contentFor 5%-85%; Levels of sweetener is 1%-10%; Essence content is 0.01%-10%; The glidant of convention amount.
Preferably, suspending agent is selected from PVP, xanthans, and bentonite, natural gum, polyethylene glycol, sodium carboxymethylcellulose,Methylcellulose, Hydroxypropyl methylcellulose, one or more in Tween-80, carragheen, carbopol and sodium alginate. Sweet tasteAgent be selected from saccharin sodium, xylitol, Aspartame, stevioside, Sucralose, honey element one or more use simultaneously, containAmount is 1%-10%. Essence is selected from the one of flavoring orange essence, flavoring apple essence, orange flavor, butter essence. Filler be selected from lactose,One in sucrose, microcrystalline cellulose, sweet mellow wine, dextrin, calcium monohydrogen phosphate and pregelatinized starch.
In a preferred mode, fexofenadine hydrochloride dry suspensoid agent, wherein contains active ingredient hydrochloric acid fexofenadineHydrochloride, content 1%-12%; Suspending agent content is 1%-10%; Filler content is 5%-60%; Levels of sweetener is 1%-0%;Essence content is 0.01%-10%; The glidant of convention amount.
Suspending agent is selected from PVP, xanthans, bentonite, natural gum, polyethylene glycol, sodium carboxymethylcellulose, methyl fiberElement, Hydroxypropyl methylcellulose, one or more in Tween-80, carragheen, carbopol and sodium alginate etc. use simultaneously, containAmount is 1%-10%.
Filler is selected from the one in lactose, sucrose, microcrystalline cellulose, sweet mellow wine, dextrin, calcium monohydrogen phosphate and pregelatinized starchOr multiple. Preferably, their use amount accounts for the 5%-60% of the mass percent of total dry suspending agent.
Sweetener is selected from one or more whiles of saccharin sodium, xylitol, Aspartame, stevioside, Sucralose, honey elementUse, content is 1%-10%; Essence be selected from flavoring orange essence, flavoring apple essence, orange flavor, butter essence one or more withIn time, is used, and content is 0.01%-10%;
The preparation method of fexofenadine hydrochloride dry suspensoid agent, comprises the following steps: (1) is by fexofenadine hydrochloride and helping80 mesh sieves are crossed in outstanding agent; (2) by filler, sweetener, the each composition of essence and glidant is crossed 100 mesh sieves; (3) after sievingEach composition mixes, packing and get final product.
The present invention do not specify down, and the degree using is all mass percentage content.
Beneficial effect
The invention provides a kind of novel form and preparation method thereof, not only can obtain by this novel form and preparation method thereof the side of takingJust, decentralization is high, be evenly distributed, and absorbs soon, and bioavilability is high, and the pharmaceutical preparation that mouthfeel is good and stable also can simultaneouslyTo facilitate production and transport, storage and clinical use.
Detailed description of the invention
Below by embodiment, technical scheme of the present invention is further elaborated. These examples of implementation are only used for illustrating the present inventionMode how to realize, claim is not done to further restriction.
Embodiment 1:
Product prescription (table 1):
Make altogether 1000 bags of techniques: fexofenadine hydrochloride and suspending agent are crossed to 80 mesh sieves, by filler, sweetener, essenceCross 100 mesh sieves with the each composition of glidant, the each composition after sieving mixes, packing and get final product.
Embodiment 2:
Product prescription (table 2):
Make altogether 1000 bags of techniques: fexofenadine hydrochloride and suspending agent are crossed to 80 mesh sieves, by filler, sweetener, essenceCross 100 mesh sieves with the each composition of glidant, the each composition after sieving mixes, packing and get final product.
Temperature and illumination experiment
Get this product (lot number 090401) of examples of implementation 1 and 2, by commercially available back, at the temperature of 60 DEG C, place 35 days, inThe 5th day and the 0th day sampling, to its settling volume ratio, related substance and activity substance content detect, and with 0 day relatively,The results are shown in Table 3. This product (lot number 090401) of getting examples of implementation 1 and 2, is placed in tool plug vial, in illumination isUnder the condition of 4500lx ± 500lx, place 35 days, in the 5th day and sampling in the 0th day, to its proterties, uniformity, content, relevantMaterial detects, and with 0 day relatively, the results are shown in Table 3.
Can find out from following form, the in the situation that of high temperature 35 days, active material is without obvious decline, settling volume than and relevantMaterial, without obvious rising, shows that this formula is more stable under the environment of high temperature and illumination.
Table 3: the temperature of the sample of examples of implementation 1 and 2 and illumination experiment result comparison sheet
The present invention not only can obtain taking convenience by this novel form and preparation method thereof, and decentralization is high, be evenly distributed, and absorbsHurry up, bioavilability is high, and the pharmaceutical preparation that mouthfeel is good and stable can also facilitate production and transport, storage and clinical making simultaneouslyWith.
Claims (2)
1. a pharmaceutical composition for fexofenadine hydrochloride, is characterized in that, said composition is divided into groups by following one-tenthBecome: active component fexofenadine hydrochloride, sodium carboxymethylcellulose, sweet mellow wine, sucrose, A SibaSweet, orange flavor, butter essence and silica, the wherein mass percent of fexofenadine hydrochlorideContent is 6%; The degree of sodium carboxymethylcellulose is 5%; The mass percentage content of sweet mellow wineBe 42%; The mass percentage content of sucrose is 40%; The mass percentage content of Aspartame is 5%;Orange flavor mass percentage content is 0.5%; Butter essence mass percentage content is 0.5%; DioxyThe mass percentage content of SiClx is 1%, and wherein, said composition exists with the form of dry suspensoid agent, wherein,Said composition is prepared by the following method, and described method is made up of the following step: (1) is by FexofenadineDetermine hydrochloride and sodium carboxymethylcellulose and cross 80 mesh sieves; (2) by sweet mellow wine, sucrose, Aspartame,Orange flavor, the each composition of butter essence and silica is crossed 100 mesh sieves; (3) the each composition after sieving is mixedClose evenly packing and get final product.
2. a pharmaceutical composition for fexofenadine hydrochloride, is characterized in that, said composition is divided into groups by following one-tenthBecome: active component fexofenadine hydrochloride, xanthans, sweet mellow wine, sucrose, Aspartame, sweet orangeEssence, butter essence and silica, wherein the mass percentage content of fexofenadine hydrochloride is 6%;The mass percentage content of xanthans is 5%; The mass percentage content of sweet mellow wine is 42%; The matter of sucroseAmount degree is 40%; The mass percentage content of Aspartame is 5%; Orange flavor quality percentageBe 0.5% than content; Butter essence mass percentage content is 0.5%; The mass percent of silicaContent is 1%, and wherein, said composition exists with the form of dry suspensoid agent; Wherein, said composition by asBelow legal system is standby, and described method is made up of the following step: (1) is by fexofenadine hydrochloride and xanthanGlue is crossed 80 mesh sieves; (2) by sweet mellow wine, sucrose, Aspartame, orange flavor, butter essence and twoThe each composition of silica is crossed 100 mesh sieves; (3) the each composition after sieving mixes, packing and get final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310606048.2A CN103610645B (en) | 2013-11-25 | 2013-11-25 | A kind of pharmaceutical composition of fexofenadine hydrochloride and preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310606048.2A CN103610645B (en) | 2013-11-25 | 2013-11-25 | A kind of pharmaceutical composition of fexofenadine hydrochloride and preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103610645A CN103610645A (en) | 2014-03-05 |
| CN103610645B true CN103610645B (en) | 2016-05-11 |
Family
ID=50161380
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310606048.2A Active CN103610645B (en) | 2013-11-25 | 2013-11-25 | A kind of pharmaceutical composition of fexofenadine hydrochloride and preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103610645B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106806346B (en) * | 2015-12-01 | 2020-09-11 | 国药集团广东环球制药有限公司 | Fexofenadine hydrochloride dry suspension preparation and preparation method thereof |
| CN107536804A (en) * | 2016-06-28 | 2018-01-05 | 浙江普利药业有限公司 | Fexofenadine hydrochloride dry suspensoid agent and preparation method thereof |
| CN114432241B (en) * | 2021-12-21 | 2023-07-14 | 上海奥全生物医药科技有限公司 | Rapidly-dispersed suspension composition, preparation method and application thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6723348B2 (en) * | 2001-11-16 | 2004-04-20 | Ethypharm | Orodispersible tablets containing fexofenadine |
| CN1813683B (en) * | 2005-12-07 | 2011-08-31 | 范敏华 | Azithromycin for suspension and its preparing method |
| DOP2006000274A (en) * | 2005-12-14 | 2007-10-15 | Sanofi Aventis Us Llc | FEXOFENADINE SUSPENSION FORMULATION |
| FR2959130A1 (en) * | 2010-04-21 | 2011-10-28 | Sanofi Aventis | PROCESS FOR PREPARING PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION COMPRISING ONE OR MORE ACTIVE INGREDIENTS AND COMPOSITIONS COMPRISING SAME |
-
2013
- 2013-11-25 CN CN201310606048.2A patent/CN103610645B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN103610645A (en) | 2014-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103269687B (en) | 4-[(S)-(4-chlorophenyl)-2-pyridinylmethoxy compositions | |
| US20170065567A1 (en) | Pharmaceutical Suspension Composition | |
| ES2791710T3 (en) | New form of administration of racecadotril | |
| JP2012505172A (en) | Liquid pharmaceutical formulation with paracetamol | |
| JP2013522185A (en) | Suspension prepared for use with rifaximin | |
| CN101390860A (en) | Desloratadine syrup and preparation method thereof | |
| CN103610645B (en) | A kind of pharmaceutical composition of fexofenadine hydrochloride and preparation method | |
| KR101947198B1 (en) | Pharmaceutical composition containing drug having poor water solubility | |
| WO2018169306A1 (en) | Aqueous liquid formulation containing choline alfoscerate | |
| ES2781755T3 (en) | Pharmaceutical composition in the form of an oral suspension comprising a flavonoic fraction and xanthan gum | |
| JP2001114696A (en) | Jerry state chinese medicine composition | |
| CN102525944A (en) | Desloratadine critrate disodium particles and preparation method for same | |
| CN106511264A (en) | Methylphenidate hydrochloride oral solution and preparation method thereof | |
| CN106361689A (en) | Fudosteine oral solution and preparation method thereof | |
| US10398728B2 (en) | Jelly-like medicinal composition of potassium iodide | |
| JP5718811B2 (en) | Oral solution | |
| WO2014002553A1 (en) | Aripiprazole oral pharmaceutical preparation | |
| JP5611672B2 (en) | Oral jelly | |
| CN101972230A (en) | Pirfenidone for suspension and preparation method | |
| KR102083621B1 (en) | Oral liquid formulation having improved stability comprising ambroxol and levodropropizine | |
| WO2013062497A1 (en) | Liquid pharmaceutical formulations | |
| CN107412174A (en) | A kind of Rupatadine fumarate oral disintegrating tablet and preparation method thereof | |
| CN102600153B (en) | Pediatric compound anisodamine hydrobromide and chlorpheniramine maleate freeze-dried orally disintegrating tablets and manufacturing method thereof | |
| JP2019151569A (en) | Orally disintegrable film preparation containing lubiprostone | |
| KR101960100B1 (en) | Film for oral cavity administration containing mirodenafil or its pharmaceutically acceptable salt |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB02 | Change of applicant information |
Address after: 311305, No. 1, Wang Shan Road, Qingshan Lake Street, Ling'an City, Zhejiang, Hangzhou Applicant after: ZHEJIANG WANSHENG PHARMACEUTICAL Co.,Ltd. Address before: 311305, No. 1, Wang Shan Road, Qingshan Lake Street, Ling'an City, Zhejiang, Hangzhou Applicant before: ZHEJIANG WANMA PHARMACEUTICAL Co.,Ltd. |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: WANMA PHARMACEUTICAL CO., LTD., ZHEJIANG TO: ZHEJIANG WANSHENG PHARMACEUTICAL CO., LTD. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address |
Address after: 311305 No.1 Wangjiashan Road, Qingshanhu Street, Lin'an City, Hangzhou City, Zhejiang Province Patentee after: Zhejiang Sansheng Mandi Pharmaceutical Co.,Ltd. Country or region after: China Address before: 311305 No.1 Wangjiashan Road, Qingshanhu Street, Lin'an City, Hangzhou City, Zhejiang Province Patentee before: ZHEJIANG WANSHENG PHARMACEUTICAL Co.,Ltd. Country or region before: China |
|
| CP03 | Change of name, title or address |